Ultragenyx Pharmaceutical Revenue and Competitors
Estimated Revenue & Valuation
- Ultragenyx Pharmaceutical's estimated annual revenue is currently $359.6M per year.
- Ultragenyx Pharmaceutical received $350.0M in venture funding in February 2019.
- Ultragenyx Pharmaceutical's estimated revenue per employee is $203,486
- Ultragenyx Pharmaceutical's total funding is $185M.
- Ultragenyx Pharmaceutical's current valuation is $4.9B. (January 2022)
Employee Data
- Ultragenyx Pharmaceutical has 1767 Employees.
- Ultragenyx Pharmaceutical grew their employee count by -3% last year.
Ultragenyx Pharmaceutical's People
Name | Title | Email/Phone |
---|---|---|
1 | Founder, CEO and President | Reveal Email/Phone |
2 | Chief Staff and SVP, Head Program and Portfolio Management | Reveal Email/Phone |
3 | CIO & SVP | Reveal Email/Phone |
4 | Executive Assistant to President & CEO | Reveal Email/Phone |
5 | Executive Director/Head Global Medical Services and Chief Staff | Reveal Email/Phone |
6 | Chief Scientific Officer | Reveal Email/Phone |
7 | VP Investor Relations | Reveal Email/Phone |
8 | VP and Site Head, Gene Therapy Manufacturing Facility (GTMF) | Reveal Email/Phone |
9 | Head HR, EMEA | Reveal Email/Phone |
10 | SVP Product Supply | Reveal Email/Phone |
Ultragenyx Pharmaceutical Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Ultragenyx Pharmaceutical?
Ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. Our company is led by an experienced management team in rare disease therapeutics. Recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. We are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. We are creating an improved model for successful rare disease drug development that increases efficiency and effectiveness by changing the way the process is organized and conducted. We believe that we can deliver significant value to our patients by building a diverse and high quality pipeline of rare disease therapeutics and efficiently transforming good science into great medicine. We are looking for highly motivated individuals to join our team in an exciting biotechnology environment. If you are looking for a meaningful position that has the ability to transform the lives of patients and be part of a high performance team focused on the same goal, this is the opportunity you have been waiting for.
keywords:Biotechnology,Healthcare,Pharmaceuticals$185M
Total Funding
1767
Number of Employees
$359.6M
Revenue (est)
-3%
Employee Growth %
$4.9B
Valuation
N/A
Accelerator
Ultragenyx Pharmaceutical News
Ultragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare...
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of...
Ultragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare...
NOVATO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Mepsevii® (vestronidase alfa) has been approve ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $657M | 2133 | -9% | N/A |
Ultragenyx Pharmaceutical Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2011-06-21 | $45.0M | A | TPG Biotech , Fidelity Biosciences | Article |
2014-07-15 | $60.2M | Undisclosed | J.P. Morgan Securities LLC | Article |
2015-02-06 | $186.3M | Undisclosed | Morgan Stanley | Article |
2015-07-16 | $Undisclosed | Undisclosed | Morgan Stanley | Article |
2016-06-08 | $65.0M | Undisclosed | Article | |
2018-01-24 | $201.2M | Undisclosed | Multiple | Article |
2018-01-25 | $287.5M | Undisclosed | Multiple | Article |
2019-02-28 | $350.0M | Undisclosed | Multiple | Article |